BCAX
Bicara Therapeutics Inc. Common Stock
$11.84
0.21
(1.81%)
| Exchange: | NASDAQ |
| Market Cap: | 646.024M |
| Shares Outstanding: |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Claire Mazumdar Clemon | |||||
| Full Time Employees: | 55 | |||||
| Address: |
|
|||||
| Website: | https://www.bicara.com |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Click to read more…
Revenue Segmentation
🔒 You are currently logged out
Income Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Balance Sheet
(* All numbers are in thousands)
🔒 You are currently logged out
Cash Flow Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Analyst Estimates
(* All numbers are in thousands)
🔒 You are currently logged out
Current Key Metrics
🔒 You are currently logged out
Forward P/E Ratios
🔒 You are currently logged out
SWOT Analysis
🔒 You are currently logged out
At what price to buy it? –
Intrinsic Value Calculator
🔒 Premium Feature
Log in to access the BCAX Intrinsic Value Calculator
Get comprehensive stock analysis with premium features
🔒 You are currently logged out
MS_Stock_Embed class not found. Please check plugin configuration.
